Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · DataMeds AI, Inc. (MEDS)

DataMEDS AI terminates letter of intent for IP and license deals paid in shares

Neutral Impact 3 of 5 m&a Written later

On November 3, 2026, DataMEDS AI terminated its Second Amended and Restated Letter of Intent dated October 19, 2026, effective immediately. The letter of intent covered IP acquisitions, a PharmacyChain license expansion, a controlling stake in Tollo Health, and REBOOT licensing, all to be paid in Company common stock, so shareholders would no longer face the share issuances it contemplated.

Key points

  • Termination notices went to EOS, Scilex, Datavault, HBA, THI and REBOOT on November 3, 2026, effective immediately.
  • The press release says the Company owes no fees or obligations as a result of the termination and will not issue any shares under the letter of intent.
  • The REBOOT GLP-1 license dated October 13, 2026 and the Datavault PharmacyChain agreement dated November 24, 2025 remain in full force and effect.

The filing

CompanyDataMeds AI, Inc. (MEDS)
Form8-K, current report
Filed with the SECNov 5, 2026, 6:08 AM ET
Accession number0001493152-26-050033

Items reported: 1.02 Termination of Material Agreement7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.